Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action.

González Larriba JL, Espinosa E, García Carbonero I, García-Donas J, López M, Meana A, Puente J, Bellmunt J.

Cancer Metastasis Rev. 2012 Sep;31 Suppl 1:S11-7. doi: 10.1007/s10555-012-9354-z. Review.

PMID:
22674353
2.

Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma.

Lamm W, Vogl UM, Bojic M, Zielinski C, Klingler C, Kramer G, Schmidinger M.

Acta Oncol. 2012 Jan;51(1):101-6. doi: 10.3109/0284186X.2011.589404. Epub 2011 Jul 8.

PMID:
21736504
3.

Temsirolimus in VEGF-refractory metastatic renal cell carcinoma.

Mackenzie MJ, Rini BI, Elson P, Schwandt A, Wood L, Trinkhaus M, Bjarnason G, Knox J.

Ann Oncol. 2011 Jan;22(1):145-8. doi: 10.1093/annonc/mdq320. Epub 2010 Jul 1.

PMID:
20595449
4.

Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma.

Rodriguez-Pascual J, Cheng E, Maroto P, Duran I.

Anticancer Drugs. 2010 Jun;21(5):478-86. Review.

PMID:
20401967
5.

Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma.

Schmidinger M, Bellmunt J.

Cancer Treat Rev. 2010 Aug;36(5):416-24. doi: 10.1016/j.ctrv.2010.01.003. Epub 2010 Feb 16. Review.

PMID:
20163917
6.

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA.

J Clin Oncol. 2009 Aug 1;27(22):3584-90. doi: 10.1200/JCO.2008.20.1293. Epub 2009 Jun 1.

7.

Sequential therapy in renal cell carcinoma.

Escudier B, Goupil MG, Massard C, Fizazi K.

Cancer. 2009 May 15;115(10 Suppl):2321-6. doi: 10.1002/cncr.24241. Review.

8.

Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma.

Gerullis H, Bergmann L, Maute L, Ecke TH, Eimer C, Bagner JW, Otto T.

Med Oncol. 2010 Jun;27(2):373-8. doi: 10.1007/s12032-009-9220-1. Epub 2009 Apr 28.

PMID:
19399651
9.

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A; RECORD-1 Study Group.

Lancet. 2008 Aug 9;372(9637):449-56. doi: 10.1016/S0140-6736(08)61039-9. Epub 2008 Jul 22.

PMID:
18653228
10.

Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.

Motzer RJ, Hudes GR, Curti BD, McDermott DF, Escudier BJ, Negrier S, Duclos B, Moore L, O'Toole T, Boni JP, Dutcher JP.

J Clin Oncol. 2007 Sep 1;25(25):3958-64.

PMID:
17761980
11.

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial.

N Engl J Med. 2007 May 31;356(22):2271-81.

12.

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.

Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML.

J Clin Oncol. 2004 Mar 1;22(5):909-18.

PMID:
14990647
13.

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.

Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M.

J Clin Oncol. 2002 Jan 1;20(1):289-96.

PMID:
11773181

Supplemental Content

Support Center